Maintenance of Bimekizumab Efficacy through 2 Years in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results from Five Phase 3 3b Trials. J of Skin 2022, 6 (6), s71. https://doi.org/10.25251/skin.6.supp.71.